Iterum Therapeutics PLC Cash Flow Conversion Efficiency
Iterum Therapeutics PLC cash flow conversion efficiency. Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) has a cash flow conversion efficiency ratio of 1.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($-7.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Iterum Therapeutics PLC (2016–2024)
Cash flow conversion efficiency of Iterum Therapeutics PLC from 2016 to 2024. This chart illustrates how Iterum Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Iterum Therapeutics PLC stock price today for real-time trading data and today's change.
Iterum Therapeutics PLC Cash Flow Conversion Ratio Explained
Iterum Therapeutics PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Iterum Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iterum Therapeutics PLC ranked by their cash flow conversion efficiency. Also see market value of Iterum Therapeutics PLC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
6.271x |
|
STS Global Income & Growth Trust PLC
LSE:STS
|
0.011x |
|
METALQUEST MINING INC.
F:E7Q
|
-0.031x |
|
Magnetic North Acquisition Corp
V:MNC
|
0.115x |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
-0.005x |
|
Madhucon Projects Limited
NSE:MADHUCON
|
-0.150x |
|
EQTEC plc
LSE:EQT
|
-0.273x |
|
Banzai International, Inc.
NASDAQ:PARA
|
-0.316x |
Annual Cash Flow Conversion Efficiency for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual cash flow conversion efficiency of Iterum Therapeutics PLC from 2016 to 2024. Review Iterum Therapeutics PLC leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.08 Million | $-26.77 Million | 6.560x | +6.79% |
| 2023-12-31 | $-6.40 Million | $-39.33 Million | 6.142x | +1030.99% |
| 2022-12-31 | $28.00 Million | $-18.47 Million | -0.660x | -109.21% |
| 2021-12-31 | $50.23 Million | $-15.84 Million | -0.315x | -129.24% |
| 2020-12-31 | $-50.56 Million | $-54.53 Million | 1.079x | -65.46% |
| 2019-12-31 | $-26.24 Million | $-81.92 Million | 3.122x | +394.67% |
| 2018-12-31 | $71.62 Million | $-75.89 Million | -1.060x | -36.74% |
| 2017-12-31 | $39.49 Million | $-30.60 Million | -0.775x | -55.47% |
| 2016-12-31 | $22.67 Million | $-11.30 Million | -0.498x | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more